Mirdametinib

Generic Name: Mirdametinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₄F_₃IN_₂O_₄

CAS Number: 391210-10-9

Unique Ingredient Identifier: 86K0J5AK6M

Background: PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1

Phase 2

Completed

Conditions: Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN

Interventions: Drug: PD-0325901

First Posted Date: 2014-03-26

Last Posted Date: 2019-01-10

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 19

Registration Number: NCT02096471

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Indiana Unversity, Indianapolis, Indiana, United States

and more 8 locations

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

Phase 1

Conditions: Colorectal Cancer

Interventions: Drug: Dacomitinib
Drug: PD-0325901
Drug: Docetaxel

First Posted Date: 2014-01-17

Last Posted Date: 2018-08-27

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 35

Registration Number: NCT02039336

Locations: 🇳🇱
Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Phase 1

Completed

Conditions: KRAS Mutant Non-Small Cell Lung Cancer
Solid Tumors

Interventions: Drug: Palbociclib
Drug: PD-0325901

First Posted Date: 2013-12-30

Last Posted Date: 2024-03-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT02022982

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: PF-05212384
Drug: PD-0325901
Drug: irinotecan

First Posted Date: 2011-05-04

Last Posted Date: 2018-10-29

Lead Sponsor: Pfizer

Target Recruit Count: 105

Registration Number: NCT01347866

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
UCLA Oncology Center, Los Angeles, California, United States
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 14 locations

MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: PD-0325901

First Posted Date: 2005-09-15

Last Posted Date: 2009-03-17

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT00174369

Locations: 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Phase 1

Terminated

Conditions: Melanoma
Colonic Neoplasms
Breast Neoplasms

Interventions: Drug: PD-0325901

First Posted Date: 2005-09-07

Last Posted Date: 2013-09-13

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT00147550

Locations: 🇺🇸
Pfizer Investigational Site, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy